ENZ-5 (D5)(C2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Dean Englehardt, et al. Applicants:

08/486,066 Serial No .:

June 7, 1995

Filed:

Title:

Sugar Moiety Labeled

Nucleotides

Group Art Unit: 1812

Petitions Examiner: Pat Faison

Enzo Diagnostics, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, New York 10022 April 15, 1999

Assistant Commissioner for Patents Washington, D.C. 20231

TERMINAL DISCLAIMER

Dear Sirs:

The owner, Enzo Biochem, Inc., of one hundred percent (100%) interest in the aboveidentified patent application hereby disclaims a terminal part of the term of the patent equivalent to the period of abandonment of the above-identified application or on any application. This terminal disclaimer applies to any patent granted on the above-identified application or on any

CERTIFICATE OF TRANSMISSION

I handy certify that this (703) 308-6916) on April 15, 1999.

Typed or printed name of passon signing this certificate

APR 19 1999
OFFICE

application that contains a specific reference under 35 U.S.C. 120, 121, or 365(c) to this application. This disclaimer is binding upon the grantee, its successors or assigns.

Accompanying this Terminal Disclaimer is a Certification under 37 C.F.R. 3.73(b).

The undersigned is an attorney of record.

The Patent Office is hereby authorized to charge the terminal disclaimer fee of \$110.00 under 37 C.F.R. 1.20(d) to Deposit Account No. 05-1135 and any other fees required in connection with this Terminal Disclaimer.

Respectfully submitted,

John J. Santalone (Registration No. 32,794) Attorney for Applicants

Enzo Diagnostics, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, New York 10022 Tel: (212) 583-0100 Facsimile: (212) 583-0150

T:\US\ENZO\ENZ\$\TERMD\$C3

THE STATEMENT BELOW IS FOR OFFICE USE ONLY

In accordance with the decision granting the petition filed on this terminal disclaimer is accepted. The period of abandonment specified above has been accepted as equivalent to months.
Petitions Examiner